Scotland · NHS Scotland MSAN
Discontinuation of lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for
MSAN(2023)26 · Level 2 · issued 29 Sep 2023
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| Discontinuation of lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for | Discontinued | — |
| devices are being discontinued and stock will be exhausted by w/c 18th December 2023. | Discontinued | — |
| Sanofi – discontinuation notification - Lyxumia | Discontinued | — |
| Registration for access to the website is available to UK healthcare professionals and | Available | — |
Provenance
Where this record's bytes came from and when they entered the record. The same fields ship with every API record (/api), so a citation can be checked against the capture. Internet-Archive recoveries are dated by the Archive's capture, never ours.
scot:msan:2023:26
- Recorded
- 13 Aug 2026 22:03 UTC
- Capture route
- Captured first-hand by ShortageSignal's scheduled check
- Read from
- NHS Scotland Medicine Supply Alert Notice (PDF)
- Captured at
- 13 Aug 2026 22:03 UTC
- Content hash
5874dc466baa5a2125dfe7508bef2bb3d7c843ce91ccc1d4ce004a35c0319b12sha256 of the captured bytes — proves what was captured, not that the source was correct- Source document
- https://www.publications.scot.nhs.uk/files/msan-2023-26.pdf ↗
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.